Indications
In the next section, we will look at the primary indications for which psychedelic-assisted therapy is being used or heavily investigated as well as key considerations for each. We will also look at which medicines have been studied for which indications.
References
Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6). 603-620.
Leary, T. (1961, September 6). Drugs, Set, and Suggestibility [Paper presentation]. 1961 American Psychological Association annual meeting.
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., ... & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033.
Romeo, B., Hermand, M., Petillion, A., Karila, L., & Benyamina A. (2021). Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Journal of Psychiatric Research, 137. 273-282.
Silveira, J., & Rockman, P. (2021). Managing Uncertainty in Mental Health Care. Oxford University Press.